ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance.

MLA

Orme, Jacob J., et al. “ADAM10 and ADAM17 Cleave PD-L1 to Mediate PD-(L)1 Inhibitor Resistance.” OncoImmunology, vol. 9, no. 1, Jan. 2020, pp. 1–11. EBSCOhost, https://doi.org/10.1080/2162402X.2020.1744980.

APA

Orme, J. J., Jazieh, K. A., Xie, T., Harrington, S., Liu, X., Ball, M., Madden, B., Charlesworth, M. C., Azam, T. U., Lucien, F., Wootla, B., Li, Y., Villasboas, J. C., Mansfield, A. S., Dronca, R. S., & Dong, H. (2020). ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. OncoImmunology, 9(1), 1–11. https://doi.org/10.1080/2162402X.2020.1744980

Chicago

Orme, Jacob J., Khalid A. Jazieh, Tiancheng Xie, Susan Harrington, Xin Liu, Matthew Ball, Benjamin Madden, et al. 2020. “ADAM10 and ADAM17 Cleave PD-L1 to Mediate PD-(L)1 Inhibitor Resistance.” OncoImmunology 9 (1): 1–11. doi:10.1080/2162402X.2020.1744980.